Luye Pharma Group Ltd

Price Chart

Risk-Adjusted Performance

Also Listed On

Luye Pharma Group Ltd (2186) Price Performance

Luye Pharma Group Ltd (2186) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at HKD2.82, down 1.74% from the previous close.

Over the past year, 2186 has traded between a low of HKD1.94 and a high of HKD4.46. The stock has gained 41.0% over this period. It is currently 36.8% below its 52-week high.

Luye Pharma Group Ltd has a market capitalization of $11.86B, with a price-to-earnings ratio of 21.21.

About Luye Pharma Group Ltd

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; and Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; research and development of antibody drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Compare Luye Pharma Group Ltd

Side-by-side comparison against top Healthcare peers.